Replicor发布了12月新临床数据(REP 9AC/REP9AC')

David_2009

回复 StephenW 的帖子

I agree. Here is my point:
The cccDNA have the half-life. This cccDNA pool needs to be recharged by the newly synthesized infective HBV or recycling of HBV core element intracelluarly. So by REP 9AC, we could block the infective HBV, however the cccDNA pool could still be recharged by the intrcelluarly replication recycling. Then the nucleoside analogous could inhibit the viral DNA polymerase, thus totally stop the cccDNA's renew. After several passge of cccDNA half-life, they will finally disappear.  

StephenW

回复 David_2009 的帖子

REP9AC does not block new infection, it only blocks the release of non-viral HBsAg. This is expected to restore immune attack against infected liver cells, thereby clearing infected liver cells (together with their pools of cccDNA) from the liver.
Since REP9AC does not block the release of new virions from infected liver cells and the recharging of the cccDNA pool, it needs some help. To block re-infection by released new virions, studyforhope suggested using Mycrludex. To block the production of new virions and recharging of the cccDNA pool, studyforhope suggested the use of antvirals.

These are all theoretical conjectures, we hope they will pan out in real life.

David_2009

回复 StephenW 的帖子

Mycrludex, as it claimed, could somehow inhibit the re-infection of HB virion into hepatocyte. However, it's still a problem that it unable to block the intracelluar recycling of HB virion. Thus, the cccDNA still has the chance to be recharged by this way ... Besides, the Mycrludex is just in the Phase I...
On the other side, NA I think could supress the viral retro-transtriptase, hence completely block the cccDNA recharging. This will be followed by the gradually decreasing of cccDNA. e.g Tenofovir, 6 years' clinical data shows no drug tolerance and is commercial available now. Could it be a choice?
Anyway, it is just my expectation and hope

咬牙硬挺

如果成立基金会，会有多少人参与呢？毕竟讨论和行动是有区别的啊

yiganxiaosan

David_2009 发表于 2011-12-19 20:33
回复 StephenW 的帖子

Mycrludex, as it claimed, could somehow inhibit the re-infection of HB virion  ...

i don't understand why REP 9RC just carry out in such a small coutry, there are so many patients in China, why they do not carry out in China with the money they have? does it expensive to be in China?

another question, is the people in China is the same as in Africa? if it work for Africans,  it will work for all human being, right?

StephenW

I don't know the answer. I am guessing:
1. to conduct a clinical trial in China, you will need the approval of sFDA, this may take time and costly;
2. you will need a local partner. Replicor had research co-operations with Chinese institutions:
Fourth Military Medical University         (People’s Republic of China)
Tropical Medicine         Institute of Guangzhou, University of Traditional Chinese Medicine, China

Finally, Bangladesh is in south-east Asia (between India and Burma). REP9AC interacts with the HBsAg, so it should work for everyone. Of course, it still needs to go through all clinical trial stages.

yiganxiaosan

StephenW 发表于 2011-12-21 12:59
I don't know the answer. I am guessing:
1. to conduct a clinical trial in China, you will need the a ...

are you in American or somewhere?

StephenW

回复 yiganxiaosan 的帖子

Australia

yiganxiaosan

StephenW 发表于 2011-12-21 13:11
回复 yiganxiaosan 的帖子

Australia

what's your job? are you a HBVer ?

you post a lot of article here

StephenW

回复 yiganxiaosan 的帖子

Retired, ex-computer programmer.